Clinical Trial Update: RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers [Phase 2]

View source ↗

Summary

Phase 2 trial comparing Radium-223 dichloride plus SABR versus SABR alone for oligometastatic prostate cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Radium-223 dichloride (Xofigo) (radium-223 dichloride)
• SABR (stereotactic ablative body radiotherapy)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2025-12-19